A retrospective cohort study to investigate the incidence of cachexia in gastric cancer patients
- Conditions
- Gastric Cancer
- Registration Number
- JPRN-UMIN000033693
- Lead Sponsor
- ONO PHARMACEUTICAL CO., LTD.
- Brief Summary
Incidence of WL was 53% at the first 12 weeks after starting first-line chemotherapy, and increased to 88% after 48 weeks. Overall survival rates were significantly associated with WL at 12, 24, and 48 weeks. Appetite loss and fatigue were more frequent and more severe in patients with WL.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 131
Not provided
Patients who meet at least one of the following exclusion criteria are not included. 1) Patients who underwent surgical operation of the gastrointestinal tract within the last 6 months excluding stent placement in the gastrointestinal tract or gastroduodenostomy 2) Patients with weight loss distinctly caused by a gastrointestinal transit disorder 3) Patients with simultaneously active, double cancer (Stage I intraepithelial carcinoma, intramucosal carcinoma, superficial bladder carcinoma, or other cancers without recurrence for 5 years or more can be registered) 4) Patients with missing of weight data over 12 weeks at the time of visit and during the subsequent medical consultation period 5) Patients who underwent puncture for ascitic fluid at the beginning of initial systemic chemotherapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The frequency of onset and the time to onset of cancer cachexia in patients who were diagnosed with unresectable advanced gastric cancer for the first time and underwent systemic chemotherapy
- Secondary Outcome Measures
Name Time Method 1) Relationship between onset of cancer cachexia and changes in laboratory parameter 2) Relationship between cancer cachexia and overall survival 3) Relationship between cancer cachexia and the continuation rate of anticancer chemotherapy 4) Relationship between cancer cachexia and the introduction rate of secondary therapy 5) Relationship between onset of cancer cachexia and introduction rate of tertiary therapy 6) Relationship between cancer cachexia and severity and incidence of anorexia and fatigue 7) Correlation between the changes in body weight of >= 5% (or if BMI < 20, changes in body weight of >2%) and changes in each laboratory parameter during the first systemic chemotherapy period at 12-week intervals evaluated from the beginning day of the first systemic chemotherapy